Trial Outcomes & Findings for PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam) (NCT NCT00703885)

Results Overview

Analysis not completed.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

16 participants

Primary outcome timeframe

Same Day

Results posted on

2014-12-22

All subjects receive both doses of active drug and placebo in randomized order.

Participant milestones
Measure	ALL SUBJECTS RECEIVE ALL 3 TREATMENTS Alprazolam Low Dose Alprazolam High Dose Placebo Sequence of administration not available for subjects
Overall Study STARTED	16
Overall Study COMPLETED	16
Overall Study NOT COMPLETED	0

Withdrawal data not reported

PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)

Baseline characteristics by cohort
Measure	ALL SUBJECTS RECEIVE ALL 3 TREATMENTS n=16 Participants Alprazolam Low Dose Alprazolam High Dose Placebo Please note that this is a cross-over design with all subjects receiving all three treatments
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	16 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Sex: Female, Male Female	6 Participants n=5 Participants
Sex: Female, Male Male	10 Participants n=5 Participants
Region of Enrollment United States	16 participants n=5 Participants

Timeframe: Same Day

Analysis not completed.

Outcome data not reported

Timeframe: Post-Rx Administration

Analysis of data not completed.

Outcome data not reported

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

UCSD

Phone: 858-534-6451